Navigation Links
Less-invasive Lymph Node Resection Following Breast Cancer Surgery Confirmed as Standard of Care in Eight-year Study Led by AGH Doctors
Date:6/5/2010

Women facing breast cancer surgery can now be certain that a less-invasive technique called sentinel node resection is just as safe and effective as the traditional surgery of removing all lymph nodes from the underarm area, according to a new study being presented today at the American Society of Clinical Oncology (ASCO) meeting by oncologists from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital (AGH) in Pittsburgh.

Chicago, IL (Vocus) June 5, 2010 -- Women facing breast cancer surgery can now be certain that a less-invasive technique called sentinel node resection is just as safe and effective as the traditional surgery of removing all lymph nodes from the underarm area, according to a new study being presented today at the American Society of Clinical Oncology (ASCO) meeting by oncologists from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital (AGH) in Pittsburgh.

The study represents the first long-term comparison of the two methods’ effect on breast cancer survival and recurrence, said Thomas B. Julian, MD, Associate Director of the Breast Care Center at AGH and one of the clinical trial’s principal investigators, along with Norman Wolmark, MD, who serves as Chair of both the NSABP and the Department of Human Oncology at AGH.

The study, which enrolled 5,611 women over a period of five years, showed no significant difference in overall survival, disease-free survival, or regional control of cancer between the sentinel node resection alone versus complete axillary dissection of the lymph nodes.

“Sentinel node resection is now clearly the standard of care for women with clinically node-negative breast cancer, which comprise the majority of patients,” Dr. Julian said. “Many women with this disease are now able to avoid the potential complications of full lymph node removal and know that their cancer is being effectively treated.”

Removing all lymph nodes from the underarm area carries the risk of difficult and sometimes permanent complications ,including lost sensation in the back of the arm, tingling, weakness and swelling (lymphedema).

Sentinel nodes are normally the first lymph nodes to receive drainage as well as cancer cells from the breast tumor. Doctors can find the sentinel nodes and remove them with a small surgical procedure. If no cancer is found, removal of the remaining lymph nodes is not necessary.

The NSAPB study was the largest prospective randomized Phase III trial designed to determine that sentinel node resection alone results in the same survival and regional control as axillary dissection.

Participants across North America and Puerto Rico were randomly assigned to undergo either a sentinel node resection with an axillary dissection, or to a sentinel node biopsy alone followed by axillary dissection if a sentinel node biopsy showed cancer.

Overall eight–year survival was 91.8 percent for the sentinel node-alone patients and 90.3 percent for those who also had an axillary dissection. Disease-free survival rates were 82.4 percent for the sentinel node group and 81.5 percent for the axillary group. Local and regional recurrence of cancer happened 61 times in the sentinel node group and 63 times in the axillary group.

“These results validate sentinel node resection as a safe and effective treatment for node-negative breast cancer patients,” Dr. Julian said.

###

Read the full story at http://www.prweb.com/releases/breast_cancer_surgery/sentinel_node_resection/prweb4094574.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. News brief: Contrast agent with MRI improves detection of lymph nodes metastases
2. Vitamin D Linked to Survival in Lymphoma Patients
3. A new target for lymphoma therapy
4. The Leukemia & Lymphoma Society Available to Comment on Findings Presented at American Society of Hematology Conference
5. Data from Phase 1 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Non-Hodgkins Lymphoma
6. Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkins Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data
7. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
8. Tumors hide out from the immune system by mimicking lymph nodes
9. Specific lymph node radiotherapy is well tolerated after surgery in early breast cancer patients
10. New class of drug kills lymphoma cells
11. Routine breast cancer biopsy might predict lymph node cancer spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , ... February 20, 2017 , ... ... offering a full range of emergency dental care at his office, Antoine Dental ... When patients experience dental emergencies, they are at risk for serious complications and ...
(Date:2/20/2017)... FL (PRWEB) , ... February 20, 2017 , ... ... gift from Constellation Brands to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art ... waves. The gift was facilitated by the Pepin Family Foundation. , “We greatly ...
(Date:2/19/2017)... ... February 19, 2017 , ... "At your fingertips" electronic access ... and the Delaware Health Information Network (DHIN) have partnered to improve connectivity of ... health information exchange, DHIN stores and shares real-time health data for more than ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken Matthews to visit ... Butler products. Ken was impressed with the safety and reliability of the Stannah ... on his show. This endorsement by Ken Matthews can be heard on News ...
(Date:2/18/2017)... MANDEVILLE, La. (PRWEB) , ... February 18, 2017 ... ... Network released today provides the latest information and contact points to easily connect ... including home care, assisted living, and elder-care funding. It also conveys material on ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, ... technologies market is expected to grow at a CAGR of 9.4% ... expected to grow at a CAGR of 9.5% from 2017 to ... in 2026. ... this report will benefit you Read on to discover how ...
(Date:2/17/2017)... Feb. 17, 2017 Theravance Biopharma, Inc. ... the "Company") today announced the presentation of positive ... orally administered pan-Janus kinase (JAK) inhibitor designed to ... Congress of the European Crohn,s and Colitis Organization ... further data from its completed Phase 1 study ...
(Date:2/17/2017)... 2017   Risperdal lawsuits involving gynecomastia (male breast ... use of the atypical antipsychotic medication continue to move ... of Common Pleas, where the state,s Risperdal docket has ... a notice posted on the Court,s website , ... March 9, 2017 at 11:00 a.m. (In Re: Risperdal ...
Breaking Medicine Technology: